Paul Tudor Jones Relay Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

$25.1 Billion
Q4 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 86,357 shares of RLAY stock, worth $294,477. This represents 0.0% of its overall portfolio holdings.

Number of Shares

86,357

Previous 80,683 7.03%

Holding current value

$294,477

Previous $571,000 37.83%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$4.12 - $6.8 $23,376 - $38,583	5,674 Added 7.03%	86,357 $355,000
Q3 2024 Nov 14, 2024	BUY	$6.23 - $9.51 $90,540 - $138,208	14,533 Added 21.97%	80,683 $571,000
Q2 2024 Aug 14, 2024	BUY	$5.9 - $8.02 $4,183 - $5,686	709 Added 1.08%	66,150 $431,000
Q1 2024 May 15, 2024	BUY	$7.5 - $12.07 $255,952 - $411,912	34,127 Added 108.98%	65,441 $543,000
Q4 2023 Feb 14, 2024	SELL	$6.01 - $11.48 $148,320 - $283,314	-24,679 Reduced 44.08%	31,314 $344,000
Q3 2023 Nov 15, 2023	BUY	$8.24 - $12.97 $461,382 - $726,229	55,993 New	55,993 $470,000
Q2 2022 Aug 15, 2022	SELL	$13.31 - $34.88 $451,501 - $1.18 Million	-33,922 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$20.26 - $32.36 $687,259 - $1.1 Million	33,922 New	33,922 $1.02 Million
Q1 2021 May 17, 2021	SELL	$32.52 - $61.53 $1.41 Million - $2.66 Million	-43,286 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$35.51 - $54.03 $850,073 - $1.29 Million	23,939 Added 123.73%	43,286 $1.8 Million
Q3 2020 Nov 16, 2020	BUY	$32.81 - $45.1 $634,775 - $872,549	19,347 New	19,347 $824,000

Others Institutions Holding RLAY

# of Institutions

207

Shares Held

159M

Call Options Held

100K

Put Options Held

26.8K

View Full List

About Relay Therapeutics, Inc.

Ticker RLAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 120,219,000
Market Cap $410M
Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...

More about RLAY

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account